Drug Database
Back to search

Belgium· BE-AMP-SAM665781-00

Rybrevant 2400 mg

A amivantamab product containing amivantamab, registered in Belgium by Janssen-Cilag International. The same ATC class is registered in 15 of our 19 countries.

ATC L01FX18

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedRybrevant 2400 mgATCL01FX18REGISTER NO.BE-AMP-SAM665781-00PACKS LISTED0CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about amivantamabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Amivantamab is registered in 15 of 19 countries.

Countries holding a registration under ATC L01FX18 (amivantamab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search amivantamab products by name

Amivantamab · ATC L01FX18

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of amivantamab costs, country by country.

Normalised to the WHO defined daily dose (75 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Amivantamab · price per daily dose (75 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$335.64
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Amivantamab
Manufacturer
Janssen-Cilag International
Country
Belgium (BE)
ATC code
L01FX18
ATC class
Amivantamab
Defined daily dose
75 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Amivantamab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All amivantamab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rybrevant
  • Liechtenstein · Rybrevant
  • Norway · Rybrevant

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/171c0840-021f-4c06-87a5-67cb9de84615
GET /v1/drugs/171c0840-021f-4c06-87a5-67cb9de84615?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Rybrevant 2400 mg",
  "name_fr": "Rybrevant 2400 mg",
  "name_nl": "Rybrevant 2400 mg",
  "amp_code": "SAM665781-00",
  "strengths": [
    "160.0000",
    "160.0000",
    "0.6000"
  ],
  "pack_count": 1,
  "substances": [
    "Amivantamab",
    "Disodium Ethylenediaminetetraacetic Acid (EDTA) Dihydrate",
    "Sodium Acetate Trihydrate",
    "Sucrose",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Amivantamab",
  "authorisation_numbers": [
    "EU/1/21/1594/004"
  ]
}
API referenceMCP serverPlans

See everything about amivantamab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console